利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

9 条记录 (耗时 0.023 秒)

    Mucin antigen vaccine
    1.
    发明授权
    Mucin antigen vaccine 有权
    粘蛋白抗原疫苗

    公开(公告)号：US08299229B2

    公开(公告)日：2012-10-30

    申请号：US10997055

    申请日：2004-11-23

    申请人： Yucheng Tang ,  Albert Deisseroth

    发明人： Yucheng Tang ,  Albert Deisseroth

    IPC分类号： C07H21/04 ,  A61K39/00 ,  A61K39/12

    CPC分类号： A61K39/0011 ,  A61K9/127 ,  A61K48/00 ,  A61K48/005 ,  A61K2039/6031 ,  C07K14/4727 ,  C07K14/70578 ,  C07K2319/00 ,  C12N7/00 ,  C12N15/85 ,  C12N15/86 ,  C12N2710/10043

    摘要： Provided are expression vectors for generating an immune response to a mucin. The vectors comprise a transcription unit encoding a secretable polypeptide, the polypeptide comprising a secretory signal, a mucin antigen and CD40 ligand. Also provided are methods of generating an immune response against cells expressing a mucin by administering an effective amount of the vector. Further provided are methods of generating an immune response against cancer cells expressing a mucin in an individual by administering an effective amount of the vector. Still further provided are methods of overcoming anergy to a mucin self antigen by administering an effective amount of the vector.

    摘要翻译： 提供了用于产生对粘蛋白的免疫应答的表达载体。 载体包含编码可分泌多肽的转录单位，所述多肽包含分泌信号，粘蛋白抗原和CD40配体。 还提供了通过施用有效量的载体产生针对表达粘蛋白的细胞的免疫应答的方法。 还提供了通过施用有效量的载体来产生针对个体中表达粘蛋白的癌细胞的免疫应答的方法。 还提供了通过施用有效量的载体克服对粘蛋白自身抗原的无反应性的方法。

    Mucin antigen vaccine
    2.
    发明申请
    Mucin antigen vaccine 有权
    粘蛋白抗原疫苗

    公开(公告)号：US20050226887A1

    公开(公告)日：2005-10-13

    申请号：US10997055

    申请日：2004-11-23

    申请人： Yucheng Tang ,  Albert Deisseroth

    发明人： Yucheng Tang ,  Albert Deisseroth

    IPC分类号： A61K39/00 ,  C07K14/47 ,  C07K14/705 ,  C12N15/09 ,  C12N15/62

    CPC分类号： A61K39/0011 ,  A61K9/127 ,  A61K48/00 ,  A61K48/005 ,  A61K2039/6031 ,  C07K14/4727 ,  C07K14/70578 ,  C07K2319/00 ,  C12N7/00 ,  C12N15/85 ,  C12N15/86 ,  C12N2710/10043

    摘要： Provided are expression vectors for generating an immune response to a mucin. The vectors comprise a transcription unit encoding a secretable polypeptide, the polypeptide comprising a secretory signal, a mucin antigen and CD40 ligand. Also provided are methods of generating an immune response against cells expressing a mucin by administering an effective amount of the vector. Further provided are methods of generating an immune response against cancer cells expressing a mucin in an individual by administering an effective amount of the vector. Still further provided are methods of overcoming anergy to a mucin self antigen by administering an effective amount of the vector.

    摘要翻译： 提供了用于产生对粘蛋白的免疫应答的表达载体。 载体包含编码可分泌多肽的转录单位，所述多肽包含分泌信号，粘蛋白抗原和CD40配体。 还提供了通过施用有效量的载体产生针对表达粘蛋白的细胞的免疫应答的方法。 还提供了通过施用有效量的载体来产生针对个体中表达粘蛋白的癌细胞的免疫应答的方法。 还提供了通过施用有效量的载体克服对粘蛋白自身抗原的无反应性的方法。

    Methods for generating immunity to antigen
    5.
    发明授权
    Methods for generating immunity to antigen 有权
    产生免疫抗原的方法

    公开(公告)号：US08828957B2

    公开(公告)日：2014-09-09

    申请号：US11009533

    申请日：2004-12-10

    申请人： Albert Deisseroth ,  Yucheng Tang ,  Wei-Wei Zhang ,  Xiang-Ming Fang

    发明人： Albert Deisseroth ,  Yucheng Tang ,  Wei-Wei Zhang ,  Xiang-Ming Fang

    IPC分类号： A61K48/00 ,  A61K38/00

    CPC分类号： C07K14/4748 ,  A61K39/0011 ,  A61K2039/545 ,  A61K2039/6031 ,  C07K14/70578 ,  C12N15/86 ,  C12N2710/10343

    摘要： Provided are methods of generating an immune response to an antigen. The method comprises priming an individual by administering an expression vector encoding the antigen. The vectors comprises a transcription unit encoding a secretable fusion protein, the fusion protein containing an antigen and CD40 ligand. Administration of a fusion protein containing the antigen and CD40 ligand is used to enhance the immune response above that obtained by vector administration alone. The invention methods may be used to generate an immune response against cancer expressing a tumor antigen such as a mucin or human papilloma viral tumor antigen and to generate an immune response against an infectious agent. Also provided is a method for simultaneously producing the expression vector and the fusion protein.

    摘要翻译： 提供了产生对抗原的免疫应答的方法。 该方法包括通过施用编码抗原的表达载体来引发个体。 载体包含编码可分泌融合蛋白的转录单元，含有抗原和CD40配体的融合蛋白。 使用含有抗原和CD40配体的融合蛋白的施用用于增强仅通过单独载体给药获得的免疫应答。 本发明的方法可用于产生针对表达肿瘤抗原例如粘蛋白或人乳头状瘤病毒肿瘤抗原的癌症的免疫应答，并产生针对感染因子的免疫应答。 还提供了同时产生表达载体和融合蛋白的方法。

    Methods for immunotherapy of cancer
    6.
    发明申请
    Methods for immunotherapy of cancer 审中-公开
    癌症免疫治疗方法

    公开(公告)号：US20060286074A1

    公开(公告)日：2006-12-21

    申请号：US11441822

    申请日：2006-05-26

    申请人： Yucheng Tang ,  Albert Deisseroth

    发明人： Yucheng Tang ,  Albert Deisseroth

    IPC分类号： A61K48/00 ,  C07K14/47 ,  C07H21/04 ,  C12N15/861

    CPC分类号： C07K14/705 ,  A01K67/0275 ,  A01K2217/05 ,  A01K2227/105 ,  A01K2267/0331 ,  A61K38/00 ,  A61K39/0011 ,  A61K2039/5256 ,  A61K2039/53 ,  C12N15/86 ,  C12N2710/10343

    摘要： Provided are methods of generating an immune response to an antigen specifically associated with tumor vascular endothelial cells (TVECA). The method comprises administering to an individual an expression vector encoding the TVECA. The vector comprises a transcription unit encoding a secretable fusion protein, the fusion protein containing a TVECA and CD40 ligand. In other methods, administration of a fusion protein containing the TVECA and CD40 ligand is used to enhance the immune response above that obtained by vector administration alone. Further methods comprise the combination therapy using an expression vector encoding a secretable TVECA fusion protein and a tumor antigen vaccine.

    摘要翻译： 提供了产生对与肿瘤血管内皮细胞（TVECA）特异性相关的抗原的免疫应答的方法。 该方法包括向个体施用编码TVECA的表达载体。 载体包含编码可分泌融合蛋白的转录单元，含有TVECA和CD40配体的融合蛋白。 在其他方法中，使用含有TVECA和CD40配体的融合蛋白的施用用于增强单独通过载体施用获得的免疫应答。 其它方法包括使用编码可分泌的TVECA融合蛋白的表达载体和肿瘤抗原疫苗的组合疗法。

    Methods for generating immunity to antigen
    7.
    发明申请
    Methods for generating immunity to antigen 有权
    产生免疫抗原的方法

    公开(公告)号：US20050226888A1

    公开(公告)日：2005-10-13

    申请号：US11009533

    申请日：2004-12-10

    申请人： Albert Deisseroth ,  Yucheng Tang ,  Wei-Wei Zhang ,  Xiang-Ming Fang

    发明人： Albert Deisseroth ,  Yucheng Tang ,  Wei-Wei Zhang ,  Xiang-Ming Fang

    IPC分类号： A61K39/00 ,  C12N15/861

    CPC分类号： C07K14/4748 ,  A61K39/0011 ,  A61K2039/545 ,  A61K2039/6031 ,  C07K14/70578 ,  C12N15/86 ,  C12N2710/10343

    摘要： Provided are methods of generating an immune response to an antigen. The method comprises priming an individual by administering an expression vector encoding the antigen. The vectors comprises a transcription unit encoding a secretable fusion protein, the fusion protein containing an antigen and CD40 ligand. Administration of a fusion protein containing the antigen and CD40 ligand is used to enhance the immune response above that obtained by vector administration alone. The invention methods may be used to generate an immune response against cancer expressing a tumor antigen such as a mucin or human papilloma viral tumor antigen and to generate an immune response against an infectious agent. Also provided is a method for simultaneously producing the expression vector and the fusion protein.

    摘要翻译： 提供了产生对抗原的免疫应答的方法。 该方法包括通过施用编码抗原的表达载体来引发个体。 载体包含编码可分泌融合蛋白的转录单元，含有抗原和CD40配体的融合蛋白。 使用含有抗原和CD40配体的融合蛋白的施用用于增强仅通过单独载体给药获得的免疫应答。 本发明的方法可用于产生针对表达肿瘤抗原如粘蛋白或人乳头状瘤病毒肿瘤抗原的癌症的免疫应答，并产生针对感染因子的免疫应答。 还提供了同时产生表达载体和融合蛋白的方法。

    Compounds and methods for treating tumors, cancer and hyperproliferative diseases
    8.
    发明授权
    Compounds and methods for treating tumors, cancer and hyperproliferative diseases 有权
    用于治疗肿瘤，癌症和过度增生性疾病的化合物和方法

    公开(公告)号：US07304092B1

    公开(公告)日：2007-12-04

    申请号：US10705483

    申请日：2003-11-11

    申请人： David J. Austin ,  Viet-Ahn A. Nguyen ,  Doris Pupowicz ,  Albert Deisseroth ,  Tao Wang ,  Enrica Lerma

    发明人： David J. Austin ,  Viet-Ahn A. Nguyen ,  Doris Pupowicz ,  Albert Deisseroth ,  Tao Wang ,  Enrica Lerma

    IPC分类号： A61K31/215

    CPC分类号： C07D307/68 ,  C07C233/09 ,  C07C2601/14 ,  C07D493/08

    摘要： The present invention relates to novel compounds, pharmaceutical compositions and methods for treating tumors, cancer and hyperproliferative diseases including psoriasis, genital warts and hyperproliferative cell growth diseases, including hyperproliferative keratinocyte diseases such as hyperkeratosis, ichthyosis, keratoderma or lichen planus. These compounds are described according to the chemical structure: where R1 is H, OH, F, Cl, Br, I, a C1-C6 optionally substituted alkyl or alkenyl group, an optionally substituted aryl group or a  group; Ra is a H, OH, C1-C10, optionally substituted alkyl or alkenyl group, an optionally substituted O—(C1-C7 alkyl group) or O-aryl group, an amine group which is optionally substituted with at least one C1-C10 alkyl group which may be optionally substituted, or a single optionally substituted aryl group, biphenyl group, (C1-C6) alkylenearyl group, (C1-C6) alkylenebiphenyl group, heteroaryl group, heterocyclic group, (C1-C6) alkylene heteroaryl group or (C1-C6) alkylene heterocyclic group; R2 is a  group; Rb is a H, OH, C1-C10, optionally substituted alkyl or alkenyl group, an optionally substituted O—(C1-C7 alkyl group) or O-aryl group, an amine group which is optionally substituted with at least one C1-C10 alkyl group which may be optionally substituted, or a single optionally substituted aryl group, biphenyl group, (C1-C6) alkylenearyl group, (C1-C6) alkylenebiphenyl group, heteroaryl group, heterocyclic group, (C1-C6) alkylene heteroaryl group or (C1-C6) alkylene heterocyclic group; R3 and R6 are each independently selected from H, OH, F, Cl, Br, I, a C1-C6 optionally substituted alkyl or alkenyl group, an optionally substituted aryl group, a carbamate, alkylene carbamate, urethane or alkylene urethane; R4 is a  group, wherein Rb is as described above; and R5 is a  group, wherein Rb is as described above, with the proviso that at least one of R1 and R2 or R4 and R5 contains an Ra or Rb group which is an amine group which is optionally substituted with at least one C1-C10 alkyl group which may be optionally substituted, or a single optionally substituted aryl group, biphenyl group, (C1-C6) alkylenearyl group, (C1-C6) alkylenebiphenyl group, heteroaryl group, heterocyclic group, (C1-C6) alkylene heteroaryl group or (C1-C6) alkylene heterocyclic group; or a stereoisomer, pharmaceutically acceptable salt, solvate, and polymorph thereof.

    摘要翻译： 本发明涉及用于治疗肿瘤的新型化合物，药物组合物和方法，包括牛皮癣，生殖器疣和过度增殖细胞生长疾病的癌症和过度增殖性疾病，包括过度增生性角化细胞疾病如角化过度，鱼鳞病，角化病或扁平苔藓。 这些化合物根据化学结构进行了描述：

    Adenoviral Vector Vaccine
    9.
    发明申请
    Adenoviral Vector Vaccine 有权
    腺病毒载体疫苗

    公开(公告)号：US20070269409A1

    公开(公告)日：2007-11-22

    申请号：US10534605

    申请日：2003-11-12

    申请人： Albert Deisseroth ,  Lixin Zhang

    发明人： Albert Deisseroth ,  Lixin Zhang

    IPC分类号： A61K48/00 ,  A61K39/00 ,  C12N15/861

    CPC分类号： A61K39/12 ,  A61K2039/5256 ,  A61K2039/53 ,  A61K2039/545 ,  A61K2039/575 ,  C07K14/005 ,  C07K14/70575 ,  C07K14/70578 ,  C07K2319/02 ,  C07K2319/40 ,  C07K2319/74 ,  C12N15/86 ,  C12N2710/10343 ,  C12N2710/10371 ,  C12N2710/20022 ,  C12N2710/20034 ,  C12N2710/20071

    摘要： Provided are adenoviral vectors for generating an immune response to antigen. The vectors comprise a transcription unit encoding a secretable polypeptide, the polypeptide comprising a secretory signal sequence upstream of a tumor antigen upstream of CD40 ligand, which is missing all or substantially all of the transmembrane domain rendering CD40L secretable. Also provided are methods of generating an immune response against cells expressing a tumor antigen by administering an effective amount of the invention vector. Further provided are methods of generating an immune response against cancer expressing a tumor antigen in an individual by administering an effective amount of the invention vector. Still further provided are methods of generating immunity to infection by human papilloma virus (HPV) by administering an effective amount of the invention vector which enocodes the E6 or E7 protein of HPV. The immunity generated is long term.

    摘要翻译： 提供用于产生对抗原的免疫应答的腺病毒载体。 载体包含编码可分泌多肽的转录单元，该多肽包含在CD40配体上游的肿瘤抗原上游的分泌信号序列，其缺失所有或基本上所有的跨膜结构域再现CD40L可分泌。 还提供了通过施用有效量的本发明载体产生针对表达肿瘤抗原的细胞的免疫应答的方法。 还提供了通过施用有效量的本发明载体产生针对表达个体肿瘤抗原的癌症的免疫应答的方法。 还提供了通过施用有效量的本发明的针对HPV的E6或E7蛋白的本发明载体来产生人乳头瘤病毒（HPV）感染免疫的方法。 产生的免疫力是长期的。